Mike Dymond

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · European Journal of Cancer · 2023 · 111 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

Jung‐Min Lee, Richard G. Moore, Sharad Ghamande et al. · Clinical Cancer Research · 2022 · 53 citations · Full text

Medicine, Oncology, Pharmacology +15

Use of a Canine Model of Atopic Dermatitis to Investigate the Efficacy of a CCR4 Antagonist in Allergen-Induced Skin Inflammation in a Randomized Study

Clare Murray, Kim Ahrens, Matt Devalaraja et al. · Journal of Investigative Dermatology · 2015 · 25 citations

Life Sciences, Dermatology, Immunology +13

Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.

Jung‐Min Lee, Richard G. Moore, Sharad Ghamande et al. · Journal of Clinical Oncology · 2020 · 19 citations

Medicine, Oncology, Pharmacology +16

Temporal cytokine and lymphoid responses to an inhaled TLR7 antedrug agonist in the cynomolgus monkey demonstrates potential safety and tolerability of this approach

John Bell, Mike Dymond, Mark Biffen et al. · Toxicology and Applied Pharmacology · 2017 · 12 citations

Life Sciences, Immunology, Pharmacology +17